Skip to content
Review Open access

Metabolic heterogeneity and functional diversity of cancer-associated fibroblasts in gastric cancer (Review)

Aug 2026 · Oncology Letters · Vol 32, pp. 1-9 · 1 citation · 108 references
Medicine

TL;DR

The present review summarizes the origins, characteristics and heterogeneity of CAFs in GC and discusses their interactions with the TME, which explores potential metabolism-targeted therapeutic strategies and outlines the broader impact of CAFs on the TME.

Abstract

Gastric cancer (GC) remains a major global health challenge characterized by poor prognosis and high mortality rates, despite advances in anticancer therapies. Increasing evidence indicates that GC is a highly stromal-rich tumor, with cancer-associated fibroblasts (CAFs) serving as key stromal components of the tumor microenvironment (TME). CAFs exhibit substantial metabolic heterogeneity, such that distinct CAF subtypes demonstrate intrinsic differences and dynamic remodeling in glucose, lipid and amino acid metabolism. This metabolic reprogramming represents not only functional diversity but also an adaptive response to microenvironmental stressors, including tumor-derived signals, hypoxia, nutrient fluctuations and oxidative stress. Through these adaptations, CAFs engage in extensive crosstalk with tumor and immune cells, thereby contributing to microenvironmental remodeling. Due to their critical role and abundance in GC, CAFs have emerged as promising therapeutic targets. The present review summarizes the origins, characteristics and heterogeneity of CAFs in GC and discusses their interactions with the TME. In addition, it summarizes the metabolic heterogeneity of CAFs, explores potential metabolism-targeted therapeutic strategies and outlines the broader impact of CAFs on the TME.

Read PDF

Similar papers

Sep 2026

Abstract A013: Tumor microenvironmental metabolites regulate cancer-associated fibroblast heterogeneity

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a prominent desmoplastic response with a high abundance of cancer-associated fibroblasts (CAFs). CAFs are a functionally and transcriptionally heterogeneous population of cells and include inflammatory CAFs (iCAFs), thought to promote tumor growth via the se...

Simon Schwoerer, Chu-Fan Cai, Jessica Stradley et al. · 0 citations
Sep 2026

Abstract A019: Tumor Nutrient Stress Regulates Cancer-associated Fibroblast Heterogeneity

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer type with a 5-year survival rate of only 13%. PDAC is unique in that up to 90% of the tumor bulk is comprised of a dense desmoplastic stroma. Enriched within PDAC’s extensive stroma are cancer-associated fibroblasts (CAFs). CAFs orchestrate tumor progression...

Marta R. Storl-Desmond, Nicole Liu, K. Forti et al. · 0 citations
Review Open access 2026

Cancer-Associated Fibroblasts-Orchestrated Immune Remodeling as a Key Driver in Liver Cancer

Overall, CAFs are central orchestrators of immune remodeling in liver cancer and contribute to the establishment of an immunosuppressive microenvironment that supports tumor progression and therapeutic resistance.

N. Porro, Silvia Marri, F. Salani et al. · 0 citations
Review Open access Oct 2026

Cancer-associated fibroblasts as key mediators of therapeutic resistance and tumor progression in colorectal cancer

Cancer-associated fibroblasts (CAFs) are instrumental in tumor progression by interacting with tumor cells, other stromal components, and the extracellular matrix (ECM) within the tumor stroma. The origin, heterogeneity, and activation mechanisms of CAFs in different cancer types have been widely reported....

Bárbara Martins de Lima Coelho, L. B. Murad, Renata Machado Brandão Costa et al. · 0 citations
Review Sep 2026

Lipid Metabolic Reprogramming in Colorectal Cancer: A Central Hub Integrating Diet, Microenvironment, and Therapy Resistance.

Colorectal cancer (CRC), a significant malignancy of the digestive system, represents a considerable threat to global health. Currently, its clinical efficacy is often limited by tumor heterogeneity and therapeutic resistance. Lipid metabolic reprogramming has been identified as a core process in CRC, not only providin...

Xiao-Ya Zong, Wei-Bing Zu, Dong Tang · 0 citations
Review Open access Oct 2026

Metabolic reprogramming in cancer-associated fibroblasts: orchestrating the tumor immune microenvironment and response to immune checkpoint blockade

Immune checkpoint blockade (ICB) has reshaped the therapeutic landscape of solid tumors. However, durable clinical benefit remains limited to a subset of patients because of primary or acquired resistance. Beyond tumor-intrinsic factors, the tumor microenvironment (TME) plays a critical role in shaping responsiveness t...

Luo-Man Gan, Zhong-Long Liu, Li-Ren Cao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.